Market News / Story
Merck’s injectable Keytruda barred in Europe as Halozyme wins injunction
Seeking Alpha ·
Seeking Alpha reports: Merck shares slipped in premarket trading on Wednesday after a Dutch court barred the company from marketing an injectable version of its blockbuster cancer therapy Keytruda in certain European markets as part of a patent dispute with Halozyme Therapeutics . Issuing the injunction, the specialized Dutch patent court of The Hague also found that Merck violated the European patent, EP 2,797,622 (EP622), issued on behalf of the San Diego, California-based Halozyme , the…